News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
CNS Drug Development Resources|
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos
Advertisement

Jim Eamma

Advertisement

Executive Director and Therapeutic Strategy Lead, Oncology, at Worldwide Clinical Trials

Articles by Jim Eamma

© photon_photo - © photon_photo - stock.adobe.com

Revolutionizing Oncology: Insights on the FDA’s Project Optimus and Dose Optimization

ByMatt Cooper, PhD,Jim Eamma
September 20th 2024

Final guidance suggests sponsors select two doses for Phase II trials with additional data requirements.

Advertisement

Latest Updated Articles

  • © photon_photo - © photon_photo - stock.adobe.com
    Revolutionizing Oncology: Insights on the FDA’s Project Optimus and Dose Optimization

    Published: September 20th 2024 | Updated:



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

2

Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development

3

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

4

Reducing Site Burden Through Better Technology Integration in Clinical Trials

5

Broad Survival Benefit from MATTERHORN Trial Highlights New Approach to Biomarker Use

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us